Showing 5101-5110 of 5957 results for "".
- Maculopathy Tied to Pentosan Polysulfate Sodium May Worsen After Drug Cessationhttps://modernod.com/news/maculopathy-tied-to-pentosan-polysulfate-sodium-may-worsen-after-drug-cessation/2478071/Pentosan polysulfate sodium (PPS)-associated maculopathy may continue for at least 10 years after drug cessation and in some cases may pose a threat to central vision, according to a case report, Reuters reported. The condition 
- Hadley Launches New Website For Those Facing Vision Losshttps://modernod.com/news/hadley-launches-new-website-for-those-facing-vision-loss/2478068/In 1920, William Hadley, a Chicago area high school teacher who lost his sight at the age of 55, revolutionized the way adults facing vision loss would learn to read again when he created his Braille by Mail system. One hundre
- US to PayNearly $2 Billion for 100 Million Doses of Pfizer, BioNTech’s COVID-19 Vaccinehttps://modernod.com/news/us-to-paynearly-2-billion-for-100-million-doses-of-pfizer-biontechs-covid-19-vaccine/2478067/Pfizer and BioNTech announced that the US government agreed to pay $1.95 billion for an initial order of 100 million doses of BNT162, an mRNA-based COVID-19 vaccine candidate being jointly developed by the companies. Under the deal, the government can also acquire up to 500 million more doses.
- Aurinia Prices $200 Million Public Offering of Common Shareshttps://modernod.com/news/aurinia-prices-200-million-public-offering-of-common-shares/2478066/Aurinia Pharmaceuticals, a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, announced the pricing of its underwritten public offering of 13,333,334 common shares. The company is currently developing the investig
- MeiraGTx Announces Positive Clinical Data of Investigational Gene Therapy for X-Linked Retinitis Pigmentosahttps://modernod.com/news/meiragtx-announces-positive-clinical-data-of-investigational-gene-therapy-for-x-linked-retinitis-pigmentosa/2478062/MeiraGTx Holdings announced 6-month data from the ongoing phase 1/2 clinical trial of AAV-RPGR, an investigational gene therapy in development for the treatment of patients with X-linked retinitis pigmentosa (XLRP) with genetically confirmed variants in the RPGR gene. Significant improve
- Rayner to Lower Carbon Footprint by More Than 800 Tons Over 5 Yearshttps://modernod.com/news/rayner-to-lower-carbon-footprint-by-more-than-800-tonnes-over-5-years/2478056/Rayner announced that changes to their manufacturing and packaging procedures will reduce CO2 greenhouse gas emissions by more than 800 tons over the next 5 years. The reduced CO2 greenhouse gas emissions are the result of three dedicated waste-reducing projects:
- Pfizer, BioNTech’s mRNA-Based COVID-19 Vaccine Shows Promise in Second Studyhttps://modernod.com/news/pfizer-biontechs-mrna-based-covid-19-vaccine-shows-promise-in-second-study/2478049/Pfizer and BioNTech announced that the most advanced of four COVID-19 vaccine candidates from their BNT162 mRNA-based vaccine program demonstrated the ability to elicit high SARS-CoV-2 neutralising titers after the second dose in an ongoing phase 1/2 study in Germany. The results, which were publ
- GenSight Biologics Reports Final REALITY Study Confirms Poor Spontaneous Recovery for LHON Patients with ND4 mutationhttps://modernod.com/news/gensight-biologics-reports-final-reality-study-confirms-poor-spontaneous-recovery-for-lhon-patients-with-nd4-mutation/2478050/GenSight Biologics reported results from the final analysis of the REALITY natural history study, which reaffirm the poor prognosis for the vast majority of Leber Hereditary Optic Neuropathy (LHON) patients with vision loss due to a mutated ND4mitochondrial gene. “The REALITY findings bols
- AffronEYE Saffron Extract Aims to Reduce Risks of Long-Term Blue-Light Induced Eye Injuryhttps://modernod.com/news/affroneye-saffron-extract-aims-to-reduce-risks-of-long-term-blue-light-induced-eye-injury/2478051/In a digital era, the increasing dependence on screens and technology particularly among gamers is prolonging exposure to blue light. Madrid, Spain-based nutraceutical company Pharmactive Biotech Products offers its proprietary affronEYE saffron ingredient, a fast
- Glaucoma Study Findings Emphasize Need for Regular Eye Checkshttps://modernod.com/news/glaucoma-study-findings-emphasize-need-for-regular-eye-checks/2478048/People with early-stage glaucoma see the contrast of visible objects in a very similar way to people without the condition, a new study has shown. Research by the University of Bradford (UK) demonstrated that the brain compensates for the changes in the eye caused by glaucoma, when looking